AstraZeneca Presents Tagrisso Leptomeningeal Disease Data
Zacks Investment Research | Jun 06, 2016 11:51PM ET
AstraZeneca plc (NYSE:AZN) presented clinical and safety data from a phase I study (BLOOM) on its lung cancer drug, Tagrisso (osimertinib), in patients with leptomeningeal (LM) disease at the annual meeting of the American Society of Clinical Oncology.
Updated results showed that Tagrisso (160 mg once daily) demonstrated activity through assessments with MRI imaging intracranial response irrespective of the T790M mutation status of patients. Additionally, Tagrisso crossed the blood-brain barrier. The drug resulted in a decline in central nervous system lesions in patients with LM disease in addition to neurological improvement. Moreover, Tagrisso demonstrated a manageable tolerability profile over a treatment period of up to 11 months.
Per the company’s press release, LM disease is a complication of epidermal growth factor receptor (EGFR) mutation-positive advanced non-small cell lung cancer (NSCLC), where cancer cells spread to the cerebrospinal fluid. LM disease affects roughly 5% of patients with NSCLC and nearly 9% of those with EGFRm NSCLC.
Considering that the treatment of LM disease is difficult, the safety, tolerability and activity profile that Tagrisso has demonstrated is promising.
We note that Tagrisso (80 mg once daily) gained accelerated approval in Nov 2015 for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor therapy. It is also approved for the treatment of patients with EGFR T790M mutation-positive locally advanced/metastatic NSCLC in the EU.
Currently, Tagrisso is also being evaluated in the adjuvant setting and in the metastatic first-line setting, including patients with brain metastases, as well as in combination with other treatments.
AstraZeneca is working on strengthening its oncology product portfolio and has several candidates in its pipeline. The company’s target is to launch at least six new medicines between 2014 and 2020.
AstraZeneca is a Zacks Rank #3 (Hold) stock. Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) , Retrophin, Inc. (NASDAQ:RTRX) and Bristol-Myers Squibb Company (NYSE:BMY) . All three stocks sport a Zacks Rank #1 (Strong Buy).
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.